CJC-1295
Symbol Cj · MW 3368 Da
Modified GHRH analog stimulating endogenous growth hormone release.
- Discovered
- 2006
- Half-life
- 1 hour
- Approval
- Not FDA-approved
Quick facts
- Category
- Hormone
- Route
- Injectable
- Molecular weight
- 3368 Da
- Half-life
- 1 hour
- Discovered
- 2006
- Approval status
- Not FDA-approved
Reported effects
- GH pulse increase
- Recovery
- Body composition
Overview
CJC-1295 is a synthetic growth hormone-releasing hormone peptide designed to stimulate the body's natural production of growth hormone. Instead of directly supplying growth hormone, CJC-1295 signals the pituitary gland to release more of its own GH. It is commonly discussed for hormone support, recovery, body composition, sleep quality, and age-related growth hormone decline. CJC-1295 without DAC has a shorter duration of action compared with the longer-acting DAC version. As a hormone peptide, its main purpose is to support the growth hormone axis through natural signaling pathways.
Evidence context
CJC-1295 evidence summary
Human clinical evidence
CJC-1295 has an approval context listed in the Peptidic database. Approved use still depends on the specific indication, formulation, labeling, and clinician guidance.
Animal, preclinical, or formulation evidence
CJC-1295 may be discussed in animal, preclinical, in vitro, or early-stage research contexts. Those evidence types are useful for orientation but should not be treated as equivalent to approved human indications.
Status and evidence strength
Peptidic lists the approval status for CJC-1295 as Not FDA-approved. The reported effects below are reference fields from the peptide database, not medical promises. Source links are included later on the page when available so readers can continue review from primary or reputable sources.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- No established approved dosage; commonly referenced range is 100–300 mcg per injection
- Typical Frequency
- 1–3 times daily depending on protocol
Dosing depends on the approved indication, formulation, titration schedule, and clinician guidance. This page is educational and not a substitute for medical advice.
Research sources
Source links included from peer-reviewed literature, clinical records, and medical databases for educational research context on CJC-1295.
Internal links
Related peptides
Frequently asked questions
What category is CJC-1295 in?
CJC-1295 is listed in the Hormone category on Peptidic.
What route is CJC-1295 associated with?
CJC-1295 is associated with the injectable route in the Peptidic database. This is descriptive route context, not a use instruction.
Is CJC-1295 approved?
Peptidic lists the approval status for CJC-1295 as: Not FDA-approved. Approval details can vary by indication and jurisdiction.
Interested in CJC-1295?
Enter your email and we'll send our recommended peptide vendor for educational research reference.
Review the peptide vendor research checklistEducational reference only · No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions. Explore the full peptide database, peptide calculator, or peptide tracker.
Last reviewed for educational accuracy: 2026-06-01